Scientific American Article, virus silver bullet (lj001)
Mar 19, 2011
Dr. Bob, could this potentially cure HIV in the future??
Benhur Lee may have discovered a medical silver bulletone that can disable HIV, the exotic Ebola virus, the common flu and possibly every kind of enveloped virus on the planet.
Working from his laboratory at the University of California, Los Angeles, Lee came across this bullet after first creating a hybrid virus, one that combined the envelope (or outer surface) of the deadly Nipah virus and the core of the benign vesicular stomatitis virus. The hybrid can infect cells but cannot replicate in them.
He then screened a library of 30,000 compounds for activity against the hybrids envelope to see if they inhibited entry into the cell. One compound, called LJ001, looked really good, Lee recalls, and it wasnt toxic to cell cultures.
After a series of studies confirmed the activity and lack of toxicity, Lee sent samples of the compound to the Galveston National Laboratory at the University of Texas Medical Branch, which has biosafety labs for testing against whole Nipah, Ebola and other deadly viruses. Amazingly, LJ001 inhibited viral entry of all of them. Lee later pitted it against HIVit worked there, too. He continued testing the compound against more viruses until the list reached 20all successes.
Additional experiments revealed that the compound failed against an entirely different class of viruses. At that point, Lee figured out LJ100s secret: it works only against viruses that have lipid envelopes, which also happen to be the most deadly ones.
The compound evidently binds to lipids in the envelope of both the virus and human cells, causing damage to both. The difference is that the cell can repair all kinds of regularly occurring insults; the genetically simpler virus has no repair mechanisms. (Newly created viruses get their lipid coats by literally ripping them off the cell membrane as they bud from infected cells.) Once the viral lipids were disabled by LJ001, they stayed that way. Lees first paper on the compounds antiviral activity appeared in the February 16 Proceedings of the National Academy of Sciences USA.
Virologist Warner C. Greene of the University of California, San Francisco, finds the work fascinating but cautions that from a therapeutic point of view, it is a very, very early finding. He notes that the membrane disruption may be more toxic than is currently appreciated. Primary cells often are much more sensitive than laboratory-adapted cells, Greene says.
Lee certainly hopes to find out. He is currently working with others at U.C.L.A. to turn the promising compound into an actual drug, which would have more going for it than just a broad-spectrum ability. I cant imagine how the virus can develop resistance to this type of drug, Lee says.
Response from Dr. Frascino
I would agree and stress Dr. Greene's comment that from a treatment perspective this is a "very, very early finding." In other words this research is extremely preliminary. So don't look for this agent on your pharmacy shelves any time soon.
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.